Novartis Counting On Depth Of Insight To Continue Success In Oncology

Its cancer pipeline planned with combinations in mind, the world’s second largest oncology company is positioned to ride the crest of the new wave in cancer drug development. Novartis is also paving new ground with quality of life research, an area of growing importance for oncology.

More from Clinical Trials

More from R&D